-
CGM Data Analysis 2.0: Functional Data Pattern Recognition and Artificial Intelligence Applications
Authors:
David C. Klonoff,
Richard M. Bergenstal,
Eda Cengiz,
Mark A. Clements,
Daniel Espes,
Juan Espinoza,
David Kerr,
Boris Kovatchev,
David M. Maahs,
Julia K. Mader,
Nestoras Mathioudakis,
Ahmed A. Metwally,
Shahid N. Shah,
Bin Sheng,
Michael P. Snyder,
Guillermo Umpierrez,
Alessandra T. Ayers,
Cindy N. Ho,
Elizabeth Healey
Abstract:
New methods of CGM data analysis are emerging that are valuable for interpreting CGM patterns and underlying metabolic physiology. These new methods use functional data analysis and artificial intelligence (AI), including machine learning (ML). Compared to traditional metrics for evaluating CGM tracing results (CGM Data Analysis 1.0), these new methods, which we refer to as CGM Data Analysis 2.0,…
▽ More
New methods of CGM data analysis are emerging that are valuable for interpreting CGM patterns and underlying metabolic physiology. These new methods use functional data analysis and artificial intelligence (AI), including machine learning (ML). Compared to traditional metrics for evaluating CGM tracing results (CGM Data Analysis 1.0), these new methods, which we refer to as CGM Data Analysis 2.0, can provide a more detailed understanding of glucose fluctuations and trends and enable more personalized and effective diabetes management strategies once translated into practical clinical solutions.
△ Less
Submitted 10 May, 2025;
originally announced May 2025.
-
Multimodal AI predicts clinical outcomes of drug combinations from preclinical data
Authors:
Yepeng Huang,
Xiaorui Su,
Varun Ullanat,
Intae Moon,
Ivy Liang,
Lindsay Clegg,
Damilola Olabode,
Ruthie Johnson,
Nicholas Ho,
Megan Gibbs,
Megan Gibbs,
Alexander Gusev,
Bino John,
Marinka Zitnik
Abstract:
Predicting clinical outcomes from preclinical data is essential for identifying safe and effective drug combinations, reducing late-stage clinical failures, and accelerating the development of precision therapies. Current AI models rely on structural or target-based features but fail to incorporate the multimodal data necessary for accurate, clinically relevant predictions. Here, we introduce Madr…
▽ More
Predicting clinical outcomes from preclinical data is essential for identifying safe and effective drug combinations, reducing late-stage clinical failures, and accelerating the development of precision therapies. Current AI models rely on structural or target-based features but fail to incorporate the multimodal data necessary for accurate, clinically relevant predictions. Here, we introduce Madrigal, a multimodal AI model that learns from structural, pathway, cell viability, and transcriptomic data to predict drug-combination effects across 953 clinical outcomes and 21,842 compounds, including combinations of approved drugs and novel compounds in development. Madrigal uses an attention bottleneck module to unify preclinical drug data modalities while handling missing data during training and inference, a major challenge in multimodal learning. It outperforms single-modality methods and state-of-the-art models in predicting adverse drug interactions, and ablations show both modality alignment and multimodality are necessary. It captures transporter-mediated interactions and aligns with head-to-head clinical trial differences for neutropenia, anemia, alopecia, and hypoglycemia. In type 2 diabetes and MASH, Madrigal supports polypharmacy decisions and prioritizes resmetirom among safer candidates. Extending to personalization, Madrigal improves patient-level adverse-event prediction in a longitudinal EHR cohort and an independent oncology cohort, and predicts ex vivo efficacy in primary acute myeloid leukemia samples and patient-derived xenograft models. Madrigal links preclinical multimodal readouts to safety risks of drug combinations and offers a generalizable foundation for safer combination design.
△ Less
Submitted 24 September, 2025; v1 submitted 4 March, 2025;
originally announced March 2025.
-
Towards Conditional Generation of Minimal Action Potential Pathways for Molecular Dynamics
Authors:
John Kevin Cava,
John Vant,
Nicholas Ho,
Ankita Shukla,
Pavan Turaga,
Ross Maciejewski,
Abhishek Singharoy
Abstract:
In this paper, we utilized generative models, and reformulate it for problems in molecular dynamics (MD) simulation, by introducing an MD potential energy component to our generative model. By incorporating potential energy as calculated from TorchMD into a conditional generative framework, we attempt to construct a low-potential energy route of transformation between the helix~$\rightarrow$~coil…
▽ More
In this paper, we utilized generative models, and reformulate it for problems in molecular dynamics (MD) simulation, by introducing an MD potential energy component to our generative model. By incorporating potential energy as calculated from TorchMD into a conditional generative framework, we attempt to construct a low-potential energy route of transformation between the helix~$\rightarrow$~coil structures of a protein. We show how to add an additional loss function to conditional generative models, motivated by potential energy of molecular configurations, and also present an optimization technique for such an augmented loss function. Our results show the benefit of this additional loss term on synthesizing realistic molecular trajectories.
△ Less
Submitted 5 January, 2022; v1 submitted 28 November, 2021;
originally announced November 2021.
-
Controlling uncertainty in aptamer selection
Authors:
Fabian Spill,
Zohar B. Weinstein,
Atena Irani Shemirani,
Nga Ho,
Darash Desai,
Muhammad H. Zaman
Abstract:
The search for high-affinity aptamers for targets such as proteins, small molecules, or cancer cells remains a formidable endeavor. Systematic Evolution of Ligands by EXponential Enrichment (SELEX) offers an iterative process to discover these aptamers through evolutionary selection of high-affinity candidates from a highly diverse random pool. This randomness dictates an unknown population distri…
▽ More
The search for high-affinity aptamers for targets such as proteins, small molecules, or cancer cells remains a formidable endeavor. Systematic Evolution of Ligands by EXponential Enrichment (SELEX) offers an iterative process to discover these aptamers through evolutionary selection of high-affinity candidates from a highly diverse random pool. This randomness dictates an unknown population distribution of fitness parameters, encoded by the binding affinities, toward SELEX targets. Adding to this uncertainty, repeating SELEX under identical conditions may lead to variable outcomes. These uncertainties pose a challenge when tuning selection pressures to isolate high-affinity ligands. Here, we present a novel stochastic hybrid model that describes the evolutionary selection of aptamers in order to explore the impact of these unknowns. To our surprise, we find that even single copies of high-affinity ligands in a pool of billions can strongly influence population dynamics, yet their survival is highly dependent on chance. We perform Monte Carlo simulations to explore the impact of environmental parameters, such as the target concentration, on selection efficiency in SELEX and identify new strategies to control these uncertainties to ultimately improve the outcome and speed of this time- and resource-intensive process.
△ Less
Submitted 28 December, 2016;
originally announced December 2016.
